Fayad Al-Haimus: The TOWAR Trial On Comaprison of Whole Blood vs Component Therapy in Trauma
Fayad Al-Haimus, Adult Thrombosis Fellow at McMaster University, shared a post on LinkedIn about a recent article by Jason L. Sperry et al, published in The New England Journal of Medicine (NEJM):
”Whole blood vs component therapy in trauma: does one save more lives?
A new trial has added to the evolving hemostatic resuscitation literature in trauma: the TOWAR trial (Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage), recently published in NEJM Group.
Trial overview: Multicenter U.S. randomized trial including 1,020 trauma patients with suspected hemorrhagic shock requiring prehospital blood transfusion, randomized 2:1 to low-titer group O whole blood versus component therapy.
Key findings:
- No significant difference in 30-day mortality between whole blood and component therapy
- Outcomes were similar even when older whole blood products were used
- Reinforces the value of early blood administration in trauma care
The message may not be that ‘whole blood doesn’t work.’
Rather, this study suggests that in hemorrhagic trauma, getting blood to patients early may matter more than the exact product being delivered.”
Title: Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage
Authors: Jason L. Sperry, Francis X. Guyette, Bryan A. Cotton, James F. Luther, Richard B. Utarnachitt, Matthew E. Kutcher, Brian J. Daley, Allan B. Peetz, Mayur B. Patel, Michael D. Goodman, Jeffrey A. Claridge, Nimitt Patel, Brian G. Harbrecht, Zain G. Hashmi, Ryan Zarychanski, Matthew D. Neal, Mark H. Yazer, Christian Martin-Gill, Laura E. Vincent, Ashley M. Harner, David E. Meyer, Andrew J. Latimer, Bryce R. Robinson, Catherine L. McKnight, William R. Hinckley, Keith R. Miller, Jan O. Jansen, Douglas Martin, Erin E. Fox, Bedda L. Rosario-Rivera, Stephen R. Wisniewski

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 02:40Aniqa Gohar: One Heart Conclave – Advancing Integrated Thrombosis Care
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India